Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argipressin to reduce blood loss during hepatic resection
2021-001806-32Phase 2Active
- Sponsor
- Sahlgrenska University Hospital
- Start
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatic neoplasm, hepatic metastasis and Benign hepatic neoplasm (BHN) comparing Argipressin (vasopressin) infusion with Placebo infusion (2 arms). Primary endpoint: Intraoperative blood loss. Started Nov 2021; status: active.
02
Drugs
vasopressin
03
Conditions
hepatic neoplasmhepatic metastasisBenign hepatic neoplasm (BHN)
Beyond the preview
Go deeper on 2021-001806-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001806-32.